Olema Pharmaceuticals (OLMA) Common Equity (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Common Equity data on file, last reported at $480.5 million in Q1 2026.

• On a quarterly basis, Common Equity rose 25.3% year-over-year to $480.5 million in Q1 2026; TTM through Mar 2026 was $480.5 million, a 25.3% increase from a year earlier, with the FY2025 full-year figure at $478.6 million, up 17.02% from the prior year.
• Common Equity for Q1 2026 stood at $480.5 million, roughly flat from $478.6 million in the prior quarter.
• Over the last five years, Common Equity for OLMA reached as high as $480.5 million in Q1 2026 and fell as low as $161.6 million in Q2 2023.
• Historically, Common Equity has averaged $285.2 million across 5 years, with a median of $253.9 million in 2023.
• Across the five-year window, Common Equity plunged 33.99% in 2023 and jumped 62.26% in 2025, its largest moves.
• Year by year, Common Equity stood at $197.5 million in 2022, then gained by 28.52% to $253.9 million in 2023, then jumped by 61.08% to $409.0 million in 2024, then increased by 17.02% to $478.6 million in 2025, then grew by 0.4% to $480.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $480.5 million in Q1 2026, $478.6 million in Q4 2025, and $307.5 million in Q3 2025.